Pharma outlook in the MENA region: an insider's view

While drugmakers tend to gravitate towards the mature markets, they’re also naturally keen to identify investment opportunities elsewhere. After all, sales outside of the EU, USA and Japan account for about 20% of the global pharmaceuticals market.

After the turn of the century, the BRICS region - comprising Brazil, Russia, India, China, and later South Africa - was heralded as the future engine of growth.

Investment in the BRICS continues, but the honorific has lost some of its shine.